Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5322 ARTÍCULOS , VIENDO DEL 2191 AL 2205

Progression of clinical markers in prodromal Parkinson's disease and dementia with Lewy bodies: a multicentre study

Joza S, Hu MT, Jung KY, Kunz D, Stefani A, Dušek P, Terzaghi M, Arnaldi D, Videnovic A, Schiess MC, Hermann W, Lee JY, Ferini-Strambi L, Lewis SJG, Leclair-Visonneau L, Oertel WH, Antelmi E, Sixel-Döring F, Cochen De Cock V, Liguori C, Liu J, Provini F, Puligheddu M, Nicoletti A, Bassetti CLA, Bušková J, Dauvilliers Y, Ferri R, Montplaisir JY, Lawton M, Kim HJ, Bes F, Högl B, Šonka K, Fiamingo G, Mattioli P, Lavadia ML, Suescun J, Woo KA, Marelli S, Martens KE, Janzen A, Plazzi G, Mollenhauer B, Fernandes M, Li Y, Cortelli P, Figorilli M, Cicero CE, Schaefer C, Guiraud L, Lanza G, Gagnon JF, Sunwoo JS, Ibrahim A, Girtler N, Trenkwalder C, Baldelli L, Pelletier A, Postuma RB; International REM Sleep Behavior Disorder Study Group.

Brain. 2023 Aug 1;146(8):3258-3272. doi: 10.1093/brain/awad072.

Parkinson's-linked LRRK2-G2019S derails AMPAR trafficking, mobility and composition in striatum with cell-type and subunit specificity

Gupta S, Guevara CA, Tielemans A, Huntley GW, Benson DL.

bioRxiv [Preprint]. 2023 Oct 17:2023.10.13.562231. doi: 10.1101/2023.10.13.562231.

Dissociable effects of dopaminergic medications on depression symptom dimensions in Parkinson's disease

Costello H, Schrag AE, Howard R, Roiser JP.

medRxiv [Preprint]. 2023 Jun 30:2023.06.30.23292073. doi: 10.1101/2023.06.30.23292073.

An overview of the worldwide distribution of LRRK2 mutations in Parkinson's disease

El Otmani H, Daghi M, Tahiri Jouti N, Lesage S.

Neurodegener Dis Manag. 2023 Dec;13(6):335-350. doi: 10.2217/nmt-2023-0025. Epub 2024 Feb 2.

A Wellness Prescription for Parkinson's: Mid to Late-Stage Disease

Pontone GM, McDaniels B, Keener AM, Subramanian I.

Am J Geriatr Psychiatry. 2023 Sep;31(9):737-747. doi: 10.1016/j.jagp.2023.02.049. Epub 2023 Mar 10.

Epigenetic modification in Parkinson's disease

Song H, Chen J, Huang J, Sun P, Liu Y, Xu L, Wei C, Mu X, Lu X, Wang W, Zhang N, Shang M, Mo M, Zhang W, Zhao H, Han F.

Front Cell Dev Biol. 2023 Jun 7;11:1123621. doi: 10.3389/fcell.2023.1123621. eCollection 2023.

The New p.F1700L LRRK2 Variant Causes Parkinson's Disease by Extensively Increasing Kinase Activity

Borsche M, Pratuseviciute N, Schaake S, Hinrichs F, Morel G, Uter J, Lohmann K, Klein C, Alessi DR, Hagenah J, Sammler E.

Mov Disord. 2023 Jun;38(6):1105-1107. doi: 10.1002/mds.29385. Epub 2023 Mar 27.

Wearable sensors and features for diagnosis of neurodegenerative diseases: A systematic review

Zhao H, Cao J, Xie J, Liao WH, Lei Y, Cao H, Qu Q, Bowen C.

Digit Health. 2023 May 16;9:20552076231173569. doi: 10.1177/20552076231173569. eCollection 2023 Jan-Dec.

Instrumented Timed Up and Go Test (iTUG)-More Than Assessing Time to Predict Falls: A Systematic Review

Ortega-Bastidas P, Gómez B, Aqueveque P, Luarte-Martínez S, Cano-de-la-Cuerda R.

Sensors (Basel). 2023 Mar 24;23(7):3426. doi: 10.3390/s23073426.

X-Chromosome Association Study in Latin American Cohorts Identifies New Loci in Parkinson Disease

Leal TP, French-Kwawu JN, Gouveia MH, Borda V, Inca-Martinez M, Mason EA, Horimoto AR, Loesch DP, Sarihan EI, Cornejo-Olivas MR, Torres LE, Mazzetti-Soler PE, Cosentino C, Sarapura-Castro EH, Rivera-Valdivia A, Medina AC, Dieguez EM, Raggio VE, Lescano A, Tumas V, Borges V, Ferraz HB, Rieder CR, Schumacher-Schuh A, Santos-Lobato BL, Velez-Pardo C, Jimenez-Del-Rio M, Lopera F, Moreno S, Chana-Cuevas P, Fernandez W, Arboleda G, Arboleda H, Arboleda Bustos CE, Yearout D, Lima-Costa MF, Tarazona E, Zabetian C, Thornton TA, O'Connor TD, Mata IF.

medRxiv [Preprint]. 2023 Feb 2:2023.01.31.23285199. doi: 10.1101/2023.01.31.23285199.

Opicapone for Parkinson's disease

Aust Prescr. 2023 Aug;46(2):42. doi: 10.18773/austprescr.2023.012.

Parkinson's Disease: Advances in Treatment and the Syntheses of Various Classes of Pharmaceutical Drug Substances

Hill DR, Huters AD, Towne TB, Reddy RE, Fogle JL, Voight EA, Kym PR.

Chem Rev. 2023 Dec 13;123(23):13693-13712. doi: 10.1021/acs.chemrev.3c00479. Epub 2023 Nov 17.

Could treatment of autonomic dysfunction in early and prodromal Parkinson's disease slow disease progression?

Doolittle JD.

J Neurophysiol. 2023 Jun 1;129(6):1279-1281. doi: 10.1152/jn.00380.2022. Epub 2023 May 4.

Exercise-Induced Autophagy Ameliorates Motor Symptoms Progressivity in Parkinson's Disease Through Alpha-Synuclein Degradation: A Review

Goenawan H, Kiasati S, Sylviana N, Megantara I, Lesmana R.

Neuropsychiatr Dis Treat. 2023 May 25;19:1253-1262. doi: 10.2147/NDT.S401416. eCollection 2023.

METTL14 is decreased and regulates m(6) A modification of α-synuclein in Parkinson's disease

He H, Zhang Q, Liao J, Lei J, Luo M, Huang J, Chen M, Shen Y, Wang J, Xu P, Xiao Y.

J Neurochem. 2023 Aug;166(3):609-622. doi: 10.1111/jnc.15882. Epub 2023 Jun 13.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias